Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Gains from Sales and Divestitures: 2021-2024

Historic Gains from Sales and Divestitures for Syndax Pharmaceuticals (SNDX) over the last 4 years, with Dec 2024 value amounting to $85,495.

  • Syndax Pharmaceuticals' Gains from Sales and Divestitures rose 839.30% to $85,495 in Q4 2024 from the same period last year, while for Dec 2024 it was $85,495, marking a year-over-year increase of 839.30%. This contributed to the annual value of $85,495 for FY2024, which is 839.30% up from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $85,495 for FY2024, which was up 839.30% from $9,102 recorded in FY2023.
  • In the past 5 years, Syndax Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $85,495 in FY2024 and a low of $5,500 during FY2021.
  • In the last 3 years, Syndax Pharmaceuticals' Gains from Sales and Divestitures had a median value of $38,750 in 2022 and averaged $44,449.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Gains from Sales and Divestitures slumped by 76.51% in 2023, and later surged by 839.30% in 2024.
  • Syndax Pharmaceuticals' Gains from Sales and Divestitures (Yearly) stood at $5,500 in 2021, then soared by 604.55% to $38,750 in 2022, then crashed by 76.51% to $9,102 in 2023, then spiked by 839.30% to $85,495 in 2024.